Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Verapamil in refractory schizophrenia: a case report.

D M Bloom, S V Tourjman, N P Nair

    Progress in Neuro-Psychopharmacology & Biological Psychiatry
    |January 1, 1987
    PubMed
    Summary

    Verapamil, a calcium channel blocker, showed potential in treating schizophrenia when added to antipsychotics. This drug significantly reduced symptom scores in a patient partially responsive to other treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Barrier enclosure in tracheostomy: a protective box for healthcare workers during the coronavirus disease 2019 pandemic.

    The Journal of laryngology and otology·2022
    Same author

    System for direct measurement of the step response of electronic devices on the picosecond time scale.

    Optics letters·2009
    Same author

    Terahertz spectroscopy of three-dimensional photonic band-gap crystals.

    Optics letters·2009
    Same author

    Deformable grating optical modulator.

    Optics letters·2009
    Same author

    Harmonic mode locking of a Nd:BEL laser using a 20-GHz dielectric resonator/optical modulator.

    Optics letters·2009
    Same author

    Pulsed FM mode locking of a Nd:BEL laser.

    Optics letters·2009

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Psychiatry

    Background:

    • Verapamil is a papaverine calcium channel blocker with established uses in cardiovascular and mood disorders.
    • Antipsychotic medications often exhibit calcium channel blocking properties, suggesting a potential link.

    Observation:

    • A case study involved a schizophrenic patient partially responsive to haloperidol treatments.
    • Verapamil was administered adjunctively, with clinical and BPRS (Brief Psychiatric Rating Scale) monitoring.

    Findings:

    • The patient's BPRS score decreased from 79 to 41 with verapamil 80 mg four times daily.
    • Symptom improvement occurred after an initial worsening at lower verapamil doses.
    • Mild fatigue was the sole reported side effect.

    Related Experiment Videos

    Implications:

    • Verapamil demonstrates potential as an adjunctive therapy for schizophrenia.
    • Further clinical trials are recommended to explore verapamil's efficacy in schizophrenia treatment.
    • This suggests a novel therapeutic avenue for managing antipsychotic-resistant schizophrenia.